

ARTICLE

Open Access

# Effects of intranasal oxytocin administration on empathy and approach motivation in women with borderline personality disorder: a randomized controlled trial

Gregor Domes<sup>1,2</sup>, Nicole Ower<sup>1</sup>, Bernadette von Dawans<sup>1,2</sup>, Franny B. Spengler<sup>1</sup>, Isabel Dziobek<sup>3</sup>, Martin Bohus<sup>4,5</sup>, Swantje Matthies<sup>6</sup>, Alexandra Philipsen<sup>7</sup> and Markus Heinrichs<sup>1,8</sup>

## Abstract

Borderline personality disorder (BPD) is characterized by severe interpersonal dysfunction with problems in social cognition, empathy and social approach. Although the neuropeptide oxytocin is known to regulate complex social cognition and behavior in healthy individuals and clinical populations, there is still a lack of evidence for a potential beneficial effect of oxytocin administration on social cognition and social approach in BPD. Fifty-one women with BPD and 51 matched healthy controls were randomized to a double-blind, placebo-controlled, between-subject experimental trial. We administered a single dose of 24 IU oxytocin or placebo intranasally prior to a standardized task measuring affective and cognitive empathy and approach motivation. All participants were free of hormonal contraception and tested in the mid-luteal phase of their menstrual cycle. In the placebo condition, patients with BPD showed reduced cognitive and affective empathy, and less approach behavior motivation than healthy controls. Intranasal oxytocin significantly increased affective empathy and approach motivation in both BPD patients and healthy controls compared to placebo. More importantly, oxytocin administration led to similar scores between BPD and healthy controls. These findings provide the first evidence for a beneficial effect of oxytocin on deficits in affective empathy and approach motivation of BPD. Our results indicate a beneficial effect of a single dose of oxytocin on affective empathy and approach motivation in women with BPD adapting their level of social functioning to healthy controls. Future clinical trials will need to investigate the long-term effects and effectiveness of oxytocin as an add-on treatment for social impairments in BPD.

## Introduction

Borderline personality disorder (BPD) is a severe psychiatric disorder characterized by a pervasive pattern of instability in relationships, affect and self-image. With a lifetime prevalence of about 2%, BPD patients account for

10% of all psychiatric outpatients and for about 20% of inpatients and thus cause tremendous costs to health systems<sup>1</sup>. To date, there is no specific pharmacological treatment available, and psychotherapy only reveals effects in parts of the patient population<sup>1</sup>. BPD patients often report problems establishing and maintaining stable relationships to significant others<sup>2</sup>. Their relationships are characterized by a pervasive fear of abandonment, anxiousness, mistrust, and conflicts which can culminate in hostile and impulsive behavior<sup>3</sup>. Interpersonal problems are among the core symptoms of the disorder, and difficulties in social interactions and social relationships

Correspondence: Gregor Domes ([domes@uni-trier.de](mailto:domes@uni-trier.de)) or Markus Heinrichs ([heinrichs@psychologie.uni-freiburg.de](mailto:heinrichs@psychologie.uni-freiburg.de))

<sup>1</sup>Department of Psychology, Laboratory for Biological and Personality Psychology, University of Freiburg, Freiburg, Germany

<sup>2</sup>Department of Biological and Clinical Psychology, University of Trier, Trier, Germany

Full list of author information is available at the end of the article

These authors contributed equally: Gregor Domes, Nicole Ower

© The Author(s) 2019



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

are associated with disadvantages in broader social functioning and social integration<sup>4,5</sup>.

Empathy as a prerequisite for intact social functioning comprises both the cognitive ability to recognize others' emotional states, and the affective process of vicariously feeling others' emotions<sup>6</sup>. Both facets of empathy form the basis for understanding and predicting other people's behavior and for regulating one's own reactions in social interactions. Although impairments in empathy have been discussed as a psychopathological factor in BPD and are defined as a core feature of BPD in the DSM-5<sup>3</sup>, the empirical evidence for impaired empathy in BPD is controversial<sup>7,8</sup>. Some studies have reported enhanced affective responding to social stimuli and better emotion recognition<sup>9–11</sup>, while others using more complex tasks demanding higher order integration of social information, resembling the challenges of real-life social situations, demonstrate empathic impairments in BPD<sup>12–14</sup>.

Oxytocin (OT) is a neuropeptide that is essentially involved in social cognition, behavior, and brain structure<sup>15–17</sup>. In humans, OT exerts behavioral and neural effects associated with social approach and avoidance: it reduces anxiety and the endocrine responses to social stressors<sup>18,19</sup>, enhances trust in social interactions<sup>20,21</sup> and strengthens positive communication in couples<sup>22</sup>. In addition, a number of studies provided evidence for enhanced emotion recognition<sup>23–25</sup> and empathy<sup>26,27</sup> following OT administration.

There is initial evidence for lower peripheral OT-levels in women with BPD, suggesting altered endogenous OT-signaling in these patients<sup>28</sup>. The exogenous administration of OT has been reported to reduce stress reactivity in BPD<sup>29</sup>, reduce avoidant reactions to threat-signaling social stimuli<sup>30</sup> and attenuate the emotional and neural responses to threat-related social signals<sup>31</sup> and emotional stimuli in general<sup>32</sup>. Taken together, these studies suggest altered endogenous OT-signaling in women with BPD, and positive effects of exogenous OT on stress reactivity as well as emotional and neural responses to threatening social stimuli<sup>5</sup>, although others have reported impaired trusting behavior after OT administration<sup>33,34</sup>.

Based on these findings, the present study aimed to investigate OT's effects on different facets of empathy and approach motivation in BPD as compared to healthy controls by assessing stimulus-based responses. Using a double-blind, placebo-controlled, between-subject design, we hypothesized that a single dose of OT given intranasally would enhance both cognitive and emotional empathy and approach motivation in BPD and a healthy control group. Including a healthy control group further allowed us to clarify whether oxytocin would normalize decreased baseline empathy and approach motivation in BPD patients to the level of healthy subjects.

## Materials and methods


### Participants

In total, 61 women diagnosed with BPD and 68 healthy women, matched for age and education, were enrolled for the study (details on sample size calculation are found in the supplemental methods). Axis I and II psychiatric disorders were diagnosed via the Mini-International Neuropsychiatric Interview<sup>35</sup> and the Structured Clinical Interview for DSM-IV Axis II Disorders<sup>36</sup>. To assess severity of BPD symptomatology patients underwent the Rating Scale for Borderline Personality Disorder (ZAN-BPD)<sup>37</sup> and the Borderline Symptom List (BSL)<sup>38</sup>. For the description of the study groups, all participants completed a set of questionnaires regarding demographic and psychopathological characteristics (for details see supplemental methods). Data of 51 BPD patients and 51 healthy controls were available for final analyses (see Fig. 1 for detailed description of enrollment and drop-outs).

All participants were free of hormonal contraception for at least 3 months and were tested in their mid-luteal cycle phase (day 18 to day 25 of the ovarian cycle) as assessed by self-report. Healthy controls were excluded from participation if they reported any Axis I and II psychiatric disorder. BPD patients were excluded if they met criteria for lifetime bipolar disorder, lifetime schizophrenia, and current alcohol or substance addiction. In both groups, pregnant and breast-feeding women were also excluded. All participants provided written-informed consent for the experimental procedures. The study was approved by the ethics committee of the University of Freiburg and registered as a clinical trial at [clinicaltrials.gov](http://clinicaltrials.gov) (NCT01243658).

### Measures

To assess empathy and approach motivation, we applied an extended version of the Multifaceted Empathy Test, MET<sup>39</sup>. The MET is an ecologically valid instrument to assess cognitive and emotional facets of empathy. The MET version used in this and previous studies<sup>27,40</sup> consists of 30 pictures showing people in emotionally-laden situations. In this version, 13 of the pictures depict people experiencing positive emotions (e.g., a sportsman being proud about winning a game or a child feeling happy cuddling its pet), whereas seventeen of the pictures show people experiencing negative emotions (e.g., a woman feeling depressed after having been slapped or a crying child in a war scene). To assess cognitive empathy, participants were asked to select the correct mental state description out of four labels given below the picture. To measure affective empathy, participants are asked to rate in separate blocks their experienced level of empathic concern for the person in the picture on a 9-point Likert scale. Approach motivation was assessed by asking the participants to rate their desire to be close to the depicted



person on another 9-point Likert scale. For each measure (cognitive and emotional empathy, and approach motivation), stimuli were presented in blocks of ten pictures, each picture followed by the respective question. Thus, all pictures were presented three times with the specific instruction for empathy and approach motivation assessment. For each participant, pictures were randomly assigned to the three blocks and presented in random order (see Fig. 2). For the whole group of participants, the linear association between affective empathy and approach motivation was high ( $r = .83, p < .001$ ), between affective and cognitive empathy modest ( $r = .33; p < .001$ ), and for cognitive empathy and approach motivation non-significant ( $r = .18; p = .06$ ).


Trial presentation and response registration was controlled by a PC running Presentation (Neurobehavioral Systems Inc, Albany, CA, USA). For statistical analyses, we calculated total scores for each task and subscores for positive and negative stimuli, by averaging the trials within a specific condition. To control for non-specific substance effects, we collected the following state measures: mood, using the Multimodal Mood Questionnaire (MDBF), anxiety using the State-Trait-Anxiety-Inventory (STAI), anger using the State-Trait-Anger-Inventory (STAXI) and distress with a visual analog scale (VAS) at three times during the time-course of the experiment: before substance application ( $t_1$ ), shortly before the experiment ( $t_2$ ) and directly after the experiment ( $t_3$ ).

### Treatment and procedures

Participants were randomly assigned to receive OT or placebo in a double-blind between-subject study design. Forty-five minutes before the empathy task started, participants self-administered 24 IU OT (or the placebo) via nasal spray (Syntocinon nasal spray, three puffs per nostril, with 4 IU per puff) under the experimenter's supervision to ensure standardized substance uptake. The placebo contained exactly the same ingredients as the OT spray except for the active agent to avoid subjective substance effects (e.g., olfactory effects). Nasal sprays were blinded by the pharmacy.

### Analysis

Group and drug effects on empathy and approach motivation were tested with separate 2-way univariate analyses of variance for total scores, and positive and negative stimuli. Two-way ANOVAs and three-way ANOVAs with time as a repeated measure were calculated to test for differences and changes in mood, anxiety, anger, and tension over the course of the experiment. To control for possible moderating effects of symptom severity within the patient group, ANCOVAs were conducted with the total scores of the Borderline Symptom List (BSL)<sup>38</sup> and the Childhood Trauma Questionnaire (CTQ). Levene's test was used to assess the equality of variances. For all analyses, the level of significance was set to  $p < 0.05$  (two-tailed). Effect sizes are reported as partial



**Fig. 2** Task design of the MET. Stimuli were randomized and presented in blocks of ten pictures. Each block was introduced by a specific instruction.

$\eta^2$  and Cohen's *d*. All analyses were calculated with SPSS, version 25 (SPSS, Chicago).

## Results

### Sample characteristics

BPD patients and healthy controls did not differ in age, education and verbal IQ (vocabulary test). With regard to all psychopathological variables (see a detailed description see supplementary materials), BPD patients exhibited significantly higher scores compared to the healthy control group (see Table 1).

Comorbidity rates in BPD patients are given in Table 1. As medication is very common in BPD, we did not exclude medicated patients except those who were taking benzodiazepines. In the present sample, 39% ( $n = 20$ ) of the patients were free of psychopharmacological medication. About 47% ( $n = 27$ ) of the patients were taking antidepressant medication and 18% ( $n = 9$ ) atypical antipsychotics.

### Cognitive empathy

The 3-way ANOVA on MET cognitive empathy (see Fig. 3a; Supplementary Table S1) revealed an overall significantly lower performance in patients with BPD compared to controls (main effect group:  $F_{(1,98)} = 5.63$ ,  $p = .020$ ,  $\eta^2 = .054$ ), but no main effect of OT (main effect drug:  $F_{(1,98)} = 0.68$ ,  $p = .41$ ) and no differential effect of OT in BPD patients and controls (group x drug interaction:  $F_{(1,98)} = 0.32$ ,  $p = .57$ ). In addition, the main effect of

valence was significant ( $F_{(1,98)} = 13.7$ ,  $p < .001$ ;  $\eta^2 = .123$ ), while the valence x group interaction ( $F_{(1,98)} = 1.26$ ,  $p = .265$ ), valence x drug interaction ( $F_{(1,98)} = 0.90$ ,  $p = .344$ ) and valence x group x drug interaction ( $F_{(1,98)} = 0.89$ ,  $p = .348$ ) were not significant.

The ANOVAs for positive stimuli confirmed lower performance in BPD patients than controls (main effect group:  $F_{(1,98)} = 8.10$ ,  $p = .005$ ,  $\eta^2 = .076$ ), but again no effect of OT (main effect drug:  $F_{(1,98)} = 0.33$ ,  $p = .856$ ) and no drug-by-group interaction ( $F_{(1,98)} = 0.01$ ,  $p = .961$ ). For negative stimuli, none of the effects was significant (main effect group:  $F_{(1,98)} = 1.60$ ,  $p = .208$ ; main effect drug:  $F_{(1,98)} = 1.25$ ,  $p = .266$ ; interaction:  $F_{(1,98)} = 0.84$ ,  $p = .362$ ).

### Affective empathy


The 3-way ANOVA on MET affective empathy (see Fig. 3b; Supplementary Table S1) revealed significantly lower affective empathy in BPD patients (main effect group:  $F_{(1,98)} = 15.47$ ,  $p < .001$ ,  $\eta^2 = .136$ ), increased affective empathy following OT treatment (main effect drug:  $F_{(1,98)} = 6.43$ ,  $p = .013$ ,  $\eta^2 = .062$ ), but no group x drug interaction ( $F_{(1,98)} = 2.81$ ,  $p = .097$ ). In addition, the valence x group interaction was significant ( $F_{(1,98)} = 28.7$ ,  $p < .001$ ;  $\eta^2 = .226$ ), while the main effect of valence ( $F_{(1,98)} = 0.35$ ,  $p = .553$ ), valence x drug interaction ( $F_{(1,98)} = 0.01$ ,  $p = .990$ ) and valence x group x drug interaction ( $F_{(1,98)} = 2.21$ ,  $p = .140$ ) did not reach significance.

**Table 1 Demographic and psychopathological characteristics (mean values and standard deviation in parantheses) of healthy controls and patients with Borderline personality disorder.**

	Healthy controls	Borderline PD	<i>p</i>
Age	31.4 (8.4)	29.4 (7.9)	.229
Vocabulary test (verbal IQ)	31.6 (7.6)	30.3 (7.6)	.325
Psychopathological scores, mean (SD)			
Zanarini Interview	–	11.3 (6.5)	
BSL sum	41.9 (29.7)	198.1 (67.4)	<.001
FDS total	2.6 (2.9)	26.4 (21.1)	<.001
BDI	3.9 (4.7)	27.2 (12.7)	<.001
CTQ	43.3 (10.8)	74.7 (20.5)	<.001
BSI	0.3 (0.33)	1.8 (0.86)	<.001
SIAS	19.5 (10.4)	38.2 (15.1)	<.001
STAI	36.0 (11.0)	62.5 (10.1)	<.001
STAXI	16.8 (5.5)	27.2 (8.1)	<.001
Axis I comorbidity, No. (%)			
Substance abuse	–	11 (20.4)	
Major depression (current)	–	20 (37.0)	
Major depression (lifetime)	–	35 (64.8)	
Dysthymia	–	12 (22.2)	
Anxiety disorder	–	23 (42.6)	
Obsessive-compulsive disorder	–	7 (13.0)	
Post-traumatic stress disorder	–	16 (29.6)	
Eating disorder	–	13 (24.1)	
Axis II comorbidity, No.(%)			
Paranoid PD	–	5 (9.3)	
Schizoid PD	–	1 (1.9)	
Obsessive-compulsive PD	–	3 (5.6)	
Avoidant PD	–	14 (25.9)	
Dependent PD	–	1 (1.9)	
Negativistic PD	–	1 (1.9)	
Depressive PD	–	6 (11.1)	

PD personality disorder, BSL borderline symptom list, FDS questionnaire for dissociative symptoms, BDI Beck depression inventory, CTQ childhood trauma questionnaire, BSI brief symptom inventory, SIAS social interaction anxiety scale, STAI state-trait anxiety inventory, STAXI state-trait anger expression inventory

Descriptive data suggest that affective empathy in BPD patients with OT reached the placebo level in healthy controls. Bonferroni-corrected *t*-tests for independent samples confirmed this impression: BPD patients with OT



exhibited significantly higher affective empathy than BPD patients with placebo ( $t(49) = -2.643, p = .011, d = -.68$ ). In addition, healthy controls with placebo and BPD patients with OT did not differ significantly ( $t(49) = -1.074, p = .288, d = .27$ ).

For positive stimuli, BPD showed lower affective empathy than controls (main effect group:  $F(1,98) = 51.31, p < .001, \eta^2 = .344$ ), OT treatment increased affective empathy in both groups (main effect drug:  $F(1,98) = 5.52, p = .021, \eta^2 = .053$ ), whereas the group x drug interaction was not significant ( $F(1,98) = 0.33, p = .568$ ). For negative stimuli, the main effect of group was not significant

( $F_{(1,98)} = .67, p = .414$ ). OT increased affective empathy in terms of a main effect ( $F_{(1,98)} = 4.16, p = .044, \eta^2 = .041$ ). In addition, the group x drug interaction was significant ( $F_{(1,98)} = 3.94, p = .049, \eta^2 = .039$ ) indicating that the effect of OT was more pronounced in BPD patients than controls.

### Approach motivation

For approach motivation (see Fig. 3c; Supplementary Table S1), the 3-way ANOVA revealed a significant main effect of group, with BPD patients showing less approach motivation than controls ( $F_{(1,98)} = 10.46, p = .002, \eta^2 = .096$ ). OT significantly increased approach motivation scores in terms of a main effect ( $F_{(1,98)} = 14.909, p = .004, \eta^2 = .079$ ). The significant group x drug interaction ( $F_{(1,98)} = 8.87, p = .004, \eta^2 = .049$ ) indicates that OT-induced increase in approach motivation was more pronounced in BPD patients than healthy controls. Notably, approach motivation scores in BPD patients with OT and healthy controls with placebo did not differ. Pair-wise comparisons confirmed that BPD patients with OT exhibited significantly more approach motivation than BPD patients with placebo ( $t(49) = -3.255, p = .002, d = -.91$ ) and that BPD patients with OT reached the level of healthy controls with placebo ( $t(49) = -.261, p = .795, d = -.08$ ). In addition, main effect of valence ( $F_{(1,98)} = 43.2, p < .001; \eta^2 = .306$ ) and valence x group interaction were significant ( $F_{(1,98)} = 7.78, p = .006; \eta^2 = .074$ ), while the valence x drug ( $F_{(1,98)} = 0.08, p = .776$ ) and valence x group x drug interaction were not significant ( $F_{(1,98)} = 1.68, p = .198$ ).

For approach motivation towards positive stimuli, the ANOVA indicated lower overall approach motivation in BPD patients (main effect group:  $F_{(1, 98)} = 26.78, p < .001, \eta^2 = .212$ ) and a significant enhancing overall effect of OT (main effect drug:  $F_{(1, 98)} = 7.81, p = .006, \eta^2 = .074$ ), whereas the group x drug interaction was not significant ( $F_{(1, 98)} = 0.77, p = .382$ ). For negative stimuli, BPD patients did not differ significantly from controls (main effect group:  $F_{(1, 98)} = 0.81, p = .372, \eta^2 = .008$ ), and OT had no general impact in terms of a main effect ( $F_{(1, 98)} = 3.83, p = .053$ ). However, the group x drug interaction was significant, indicating that the effect of OT was more pronounced in BPD patients than controls ( $F_{(1, 98)} = 5.12, p = .026, \eta^2 = .050$ ).

The effects within the BPD group were not moderated by symptom severity as ANCOVAs with BSL (Cognitive Empathy:  $F_{(1,48)} = 0.805, p = .374, \eta^2 = .017$ ; Affective Empathy:  $F_{(1,48)} = 0.106, p = .746, \eta^2 = .002$ ; Approach Motivation:  $F_{(1,48)} = 0.025, p = .875, \eta^2 = .001$ ) and CTQ (Cognitive Empathy:  $F_{(1,48)} = 0.07, p = .792, \eta^2 = .001$ ; Affective Empathy:  $F_{(1,48)} = 2.729, p = .105, \eta^2 = .054$ ; Approach Motivation:  $F_{(1,48)} = 3.448, p = .069, \eta^2 = .067$ ) scores as covariates revealed no significant results.

### Non-specific oxytocin effects

To control for non-specific effects of OT over the course of the experiment, we tested for OT effects on self-reported mood, anxiety, anger, and distress. Values for mood increased over time, whereas anxiety and anger values decreased over time and distress did not change over time. We observed no significant interaction (time x group x drug) in any of the measures. In sum, OT had no non-specific effect on mood, anxiety, anger and distress (see supplemental results for a detailed description; descriptive data is given in Supplementary Table S2).

### Discussion

In the present study, patients with BPD showed reduced cognitive and affective empathy, and less approach behavior motivation than a healthy control group, especially for positive social stimuli. A single-dose of OT given intranasally did not significantly influence cognitive empathy, but did significantly enhance affective empathy and approach behavior motivation in BPD patients and healthy controls. Patients with BPD who received OT attained a level of affective empathy and approach motivation similar to healthy controls with placebo. For positive social stimuli, both groups exhibited comparable benefits from OT administration. For negative stimuli, BPD patients showed remarkable improvements under OT, whereas healthy controls revealed no OT-induced alterations.

Our findings of impaired cognitive and affective empathy in BPD are in line with previous studies using the same experimental task<sup>12</sup> as well as studies applying different measures to assess empathy in BPD<sup>14,41,42</sup>. Our findings support the hypothesis that apart from heightened sensitivity for social cues in BPD, patients exhibit deficits in integrating complex social information, which may contribute to social impairments and interpersonal difficulties<sup>14,43</sup>. Importantly, in analyzing our data for positive and negative stimuli separately, we show that empathy and approach motivation alterations in BPD are mainly driven by impaired responding to positive stimuli, while there is no such difference for negative stimuli. It appears that BPD patients more easily empathize with people in aversive situations or in distress, while it is difficult for them to be empathic with people in positive social situations or people experiencing positive emotions. This pattern is plausible, as negative emotions and situations are much more familiar to patients with BPD and thus negative emotions might be more easily accessible for BPD patients<sup>44</sup>.

A recent meta-analysis showed that OT enhances facial emotion recognition, which conceptually overlaps with the cognitive facet of empathy as measured with the MET<sup>25</sup>. In contrast, we found no enhancing effect of OT over cognitive empathy in the present study. We assume

that this might be due to differences in the experimental task or stimuli presented, as most previous studies used emotional faces or pictures of the eye region. In the present study, we presented complex scenes of individuals in emotionally-laden situations, challenging the participants' ability to integrate context information with facial expressions and perspective taking to infer complex affective mental states rather than recognize basic emotions. On the other hand, our results are in line with studies that tested the effects of OT in healthy samples using the MET and reported no substance effect on cognitive empathy but an enhancing effect on affective empathy<sup>27,45</sup>. Further evidence arises from studies using empathy to others' pain as a paradigm to assess OT's effects on affective empathy e.g., ref.<sup>46</sup>.

Aberrant approach behavior motivation in the BPD group concurs with clinical experiences in BPD, emphasizing rapid alterations between over-involvement and withdrawal as one of the core symptoms of the disorder<sup>3</sup> and findings from attachment research<sup>47</sup>. Extending the standard MET, the present study provides the first experimental evidence for reduced approach motivation in BPD compared to healthy controls. Notably, we found that OT enhanced approach motivation in our sample using this experimental paradigm to measure approach motivation. It should be noted that affective empathy and approach motivation correlated closely. Thus, affective empathy might be considered the socio-affective prerequisite of the desire to approach others. It is also possible that the reverse is true or that both affective empathy and approach motivation are related to other variables and that OT increased liking or general interest in the other person. There is strong evidence in animal studies of the approach enhancing effects of OT<sup>48</sup> and these have been also repeatedly reported in humans<sup>15</sup>. Thus, OT's beneficial effects in terms of enhancing approach motivation in BPD to a normal level might be a promising starting point for OT-enhanced behavioral interventions in situations of dysfunctional avoidance. However, it is important to keep in mind that in certain other situations, increased approach behavior might also be maladaptive for BPD patients, requiring careful therapeutic supervision. Moreover, since BPD is also known for maladaptive approach behavior in social interaction (e.g., excessive anger expression), future studies will need to investigate adaptive versus maladaptive approach situations further. As the level of approach in BPD under OT was similar to healthy controls in our study, our findings do not reflect a maladaptive 'overapproaching' but rather a normalized approach. Future clinical trials are needed to provide direct evidence for the usefulness of exogenous OT in BPD and other disorders characterized by altered social approach, e.g., autism spectrum conditions<sup>49–51</sup> and social anxiety disorder<sup>52</sup>.

Although OT increased empathy and motivational approach to positive stimuli in both BPD patients and healthy controls to the same extent, the effect was more pronounced in BPD patients for negative stimuli. Previous studies have shown that BPD patients exhibit higher trait anxiety and enhanced limbic activity in response to threat-related social stimuli<sup>31</sup>. In addition, a previous functional imaging study provided evidence for reduced amygdala reactivity in female BPD patients after OT treatment<sup>31</sup>. Thus, in the present study, the OT increase in empathy and approach motivation to negative stimuli might be attributable to OT-induced reduction of amygdala-related arousal. Given that earlier studies as well as this study's results suggest that BPD patients have difficulty processing positive social cues, stimulus valence needs further investigation in the future.

This study has some limitations. First of all, only female participants were investigated. As the effects of exogenous OT might be different for women and men<sup>53</sup>, the present results might not apply to male patients. Furthermore, both empathy and approach motivation were assessed using self-reported ratings, although we chose a stimulus-associated approach. Future studies are needed to confirm the present results using situations explicitly triggering empathic and approach-related behavior. In addition, as we included patients taking psychoactive medication targeting serotonergic and dopaminergic neurotransmission, we cannot exclude interactions between OT and medication in these patients. Finally, since we had no clinical control group, our findings' specific validity will need to be investigated in future studies by comparing different clinical groups or using a dimensional approach with participants varying in their social avoidance and empathy.

## Conclusion

The present study demonstrates for the first time that a single dose of OT given intranasally improves affective empathy and approach motivation in women with BPD. Our results may have clinical implications, as they suggest that socio-affective deficits in BPD might be specifically targeted via an intervention in the OT system. These results could provide the starting point for designing controlled clinical trials, focusing on treatment efficiency using OT as an add-on treatment to cognitive behavioral psychotherapy in BPD, while taking practical issues into account such as the route of delivery of the peptide<sup>54</sup>, as well as timing and dosage<sup>55</sup>.

## Acknowledgements

The authors thank Frederike Bjeregaard, M.Sc., Vera Engel, M.Sc., Judith Grossmann, M.Sc., Elisabeth Kraus, and Teresa Travi for their assistance during data collection. M.H. gratefully acknowledges support from the German Research Foundation (DFG) and the Research Innovation Fund of the Albert-Ludwigs-University of Freiburg. N.O. was supported by a research fellowship of

the FAZIT Foundation. None of the funders played any role in designing and conducting the study, analyzing and interpreting the data, or in the decision to publish the results or writing the manuscript.

#### Author details

<sup>1</sup>Department of Psychology, Laboratory for Biological and Personality Psychology, University of Freiburg, Freiburg, Germany. <sup>2</sup>Department of Biological and Clinical Psychology, University of Trier, Trier, Germany. <sup>3</sup>Department of Psychology, Clinical Psychology of Social Interaction, Humboldt-Universität zu Berlin, Berlin, Germany. <sup>4</sup>Institute of Psychosomatic and Psychiatric Psychotherapy, Central Institute of Mental Health, Heidelberg University, Mannheim, Germany. <sup>5</sup>McLean Hospital Harvard Medical School, Boston, MA, USA. <sup>6</sup>Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany. <sup>7</sup>Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany. <sup>8</sup>Freiburg Brain Imaging Center, University Medical Center, University of Freiburg, Freiburg, Germany

#### Conflict of interest

The authors declare that they have no conflict of interest.

#### Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Supplementary Information** accompanies this paper at (<https://doi.org/10.1038/s41398-019-0658-4>).

Received: 18 April 2019 Revised: 4 November 2019 Accepted: 6 November 2019

Published online: 04 December 2019

#### References

- Lieb, K., Zanarini, M. C., Schmahl, C., Linehan, M. M. & Bohus, M. Borderline personality disorder. *Lancet* **364**, 453–461 (2004).
- Gunderson, J. G. Borderline personality disorder. *N. Engl. J. Med.* **364**, 2037–2042 (2011).
- American Psychiatric Association. *Diagnostic and statistical manual of mental disorders: DSM-V*. (American Psychiatric Association, Washington, DC, 2013)
- Lis, S., Bohus, M. Social interaction in borderline personality disorder. *Curr. Psychiatry Rep.* <https://doi.org/10.1007/s11920-012-0338-z> (2013).
- Stanley, B. & Siever, L. J. The interpersonal dimension of borderline personality disorder: toward a neuropeptide model. *Am. J. Psychiatry* **167**, 24–39 (2010).
- Walter, H. Social cognitive neuroscience of empathy: concepts, circuits, and genes. *Emot. Rev.* **4**, 9–17 (2012).
- Dinsdale, N. & Crespi, B. J. The borderline empathy paradox: evidence and conceptual models for empathic enhancements in borderline personality disorder. *J. Pers. Disord.* **27**, 172–95. (2013).
- Domes, G., Schulze, L. & Herpertz, S. C. Emotion recognition in borderline personality disorder—a review of the literature. *J. Pers. Disord.* **23**, 6–19 (2009).
- Fertuck, E. A. et al. Enhanced 'Reading the Mind in the Eyes' in borderline personality disorder compared to healthy controls. *Psychol. Med.* **39**, 1979–1988 (2009).
- Franzen, N. et al. Superior 'theory of mind' in borderline personality disorder: an analysis of interaction behavior in a virtual trust game. *Psychiatry Res.* **187**, 224–233 (2011).
- Schulze, L., Domes, G., Köppen, D. & Herpertz, S. C. Enhanced detection of emotional facial expressions in borderline personality disorder. *Psychopathology* **46**, 217–224 (2013).
- Dziobek, I. et al. Neuronal correlates of altered empathy and social cognition in borderline personality disorder. *NeuroImage* **57**, 539–548 (2011).
- Minzenberg, M. J., Poole, J. H. & Vinogradov, S. Social-emotion recognition in borderline personality disorder. *Compr. Psychiatry* **47**, 468–474 (2006).
- Preissler, S., Dziobek, I., Ritter, K., Heekeren, H. R. & Roepke, S. Social cognition in borderline personality disorder: evidence for disturbed recognition of the emotions, thoughts, and intentions of others. *Front. Behav. Neurosci.* **4**, 182 (2010).
- Meyer-Lindenberg, A., Domes, G., Kirsch, P. & Heinrichs, M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. *Nat. Rev. Neurosci.* **12**, 524–538 (2011).
- Dannlowski, U. et al. Disadvantage of social sensitivity: interaction of oxytocin receptor genotype and child maltreatment on brain structure. *Biol. Psychiatry* **80**, 398–405 (2016).
- Bachner-Melman, R., Ebstein, R. P. in *Handbook of Clinical Neurology* pp 53–68. (Elsevier, 2014).
- Chen, F. S. et al. Common oxytocin receptor gene (OXTR) polymorphism and social support interact to reduce stress in humans. *Proc. Natl Acad. Sci. USA* **108**, 19937–19942. (2011).
- Heinrichs, M., Baumgartner, T., Kirschbaum, C. & Ehlert, U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. *Biol. Psychiatry* **54**, 1389–1398. (2003).
- Baumgartner, T., Heinrichs, M., Vonlanthen, A., Fischbacher, U. & Fehr, E. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. *Neuron* **58**, 639–650. (2008).
- Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U. & Fehr, E. Oxytocin increases trust in humans. *Nature* **435**, 673–676 (2005).
- Ditzen, B. et al. Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. *Biol. Psychiatry* **65**, 728–731 (2009).
- Domes, G., Heinrichs, M., Michel, A., Berger, C. & Herpertz, S. C. Oxytocin improves 'mind-reading' in humans. *Biol. Psychiatry* **61**, 731–733 (2007).
- Marsh, A. A., Yu, H. H., Pine, D. S. & Blair, R. J. Oxytocin improves specific recognition of positive facial expressions. *Psychopharmacol. (Berl)* **209**, 225–232. (2010).
- Shahrestani, S., Kemp, A. H. & Guastella, A. J. The impact of a single administration of intranasal oxytocin on the recognition of basic emotions in humans: a meta-analysis. *Neuropsychopharmacology* **38**, 1929–1936 (2013).
- Bartz, J. et al. Oxytocin selectively improves empathic accuracy. *Psychological Sci.* **21**, 1426–1428 (2010).
- Hurllemann, R. et al. Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. *J. Neurosci.* **30**, 4999–5007 (2010).
- Bertsch, K., Schmidinger, I., Neumann, I. D. & Herpertz, S. C. Reduced plasma oxytocin levels in female patients with borderline personality disorder. *Horm. Behav.* **63**, 424–429 (2013).
- Simeon, D. et al. Oxytocin administration attenuates stress reactivity in borderline personality disorder: a pilot study. *Psychoneuroendocrinology* **36**, 1418–1421 (2011).
- Brune, M. et al. Oxytocin influences avoidant reactions to social threat in adults with borderline personality disorder. *Hum. Psychopharmacol.* **28**, 552–561 (2013).
- Bertsch, K. et al. Oxytocin and reduction of social threat hypersensitivity in women with borderline personality disorder. *Am. J. Psychiatry* **170**, 1169–1177 (2013).
- Lischke, A., Herpertz, S. C., Berger, C., Domes, G. & Gamer, M. Divergent effects of oxytocin on (para-)limbic reactivity to emotional and neutral scenes in females with and without borderline personality disorder. *Soc. Cogn. Affect Neurosci.* **12**, 1783–1792 (2017).
- Ebert, A. et al. Modulation of interpersonal trust in borderline personality disorder by intranasal oxytocin and childhood trauma. *Soc. Neurosci.* **8**, 305–313 (2013).
- Bartz, J. et al. Oxytocin can hinder trust and cooperation in borderline personality disorder. *Soc. Cogn. Affect Neurosci.* **6**, 556–563 (2011).
- Sheehan, D. V. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J. Clin. Psychiatry* **59**(Suppl 20), 22–33 (1998). quiz 34–57.
- First, M. B., Gibbon, M., Spitzer, R. L., Benjamin, L. S. *User's guide for the structured clinical interview for DSM-IV axis I personality disorders: SCID-II*. (American Psychiatric Pub, 1997).
- Zanarini, M. C. et al. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. *J. Pers. Disord.* **17**, 233–242 (2003).
- Bohus, M. et al. Psychometric properties of the Borderline Symptom List (BSL). *Psychopathology* **40**, 126–132 (2007).
- Dziobek, I. et al. Dissociation of cognitive and emotional empathy in adults with Asperger syndrome using the Multifaceted Empathy Test (MET). *J. Autism Dev. Disord.* **38**, 464–473 (2008).



40. Domes, G., Hollerbach, P., Vohs, K., Mokros, A. & Habermeyer, E. Emotional empathy and psychopathy in offenders: an experimental study. *J. Pers. Disord.* **27**, 67–84 (2013).
41. Harari, H., Shamay-Tsoory, S. G., Ravid, M. & Levkovitz, Y. Double dissociation between cognitive and affective empathy in borderline personality disorder. *Psychiatry Res.* **175**, 277–279 (2010).
42. Mier, D. et al. Neuronal correlates of social cognition in borderline personality disorder. *Soc. Cogn. Affect Neurosci.* **8**, 531–537 (2013).
43. Liebke, L. et al. Difficulties with being socially accepted: An experimental study in borderline personality disorder. *J. Abnorm Psychol.* **127**, 670–682 (2018).
44. Law, M. K., Fleeson, W., Arnold, E. M. & Furr, R. M. Using negative emotions to trace the experience of borderline personality pathology: interconnected relationships revealed in an experience sampling study. *J. Pers. Disord.* **30**, 52–70 (2016).
45. Geng, Y. et al. Oxytocin enhancement of emotional empathy: generalization across cultures and effects on amygdala activity. *Front. Neurosci.* <https://doi.org/10.3389/fnins.2018.00512> (2018).
46. Abu-Akel, A., Palgi, S., Klein, E., Decety, J. & Shamay-Tsoory, S. Oxytocin increases empathy to pain when adopting the other- but not the self-perspective. *Soc. Neurosci.* **10**, 7–15 (2015).
47. Buchheim, A. & Diamond, D. Attachment and borderline personality disorder. *Psychiatr. Clin. North Am.* **41**, 651–668 (2018).
48. Donaldson, Z. R. & Young, L. J. Oxytocin, vasopressin, and the neurogenetics of sociality. *Science* **322**, 900–904 (2008).
49. Domes, G., Kumbier, E., Heinrichs, M. & Herpertz, S. C. Oxytocin promotes facial emotion recognition and amygdala reactivity in adults with asperger syndrome. *Neuropsychopharmacology* **39**, 698–706 (2014).
50. Domes, G. et al. Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. *Biol. Psychiatry* **74**, 164–171 (2013).
51. Yamasue, H. et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. *Mol. Psychiatry* <https://doi.org/10.1038/s41380-018-0097-2> (2018).
52. Labuschagne, I. et al. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. *Neuropsychopharmacology* **35**, 2403–2413 (2010).
53. Kanat, M., Heinrichs, M. & Domes, G. Oxytocin and the social brain: neural mechanisms and perspectives in human research. *Brain Res.* **1580**, 160–171 (2014).
54. Quintana, D. S., Alvares, G. A., Hickie, I. B. & Guastella, A. J. Do delivery routes of intranasally administered oxytocin account for observed effects on social cognition and behavior? A two-level model. *Neurosci. Biobehav. Rev.* **49**, 182–192 (2015).
55. Spengler, F. B. et al. Kinetics and Dose Dependency of Intranasal Oxytocin effects on amygdala reactivity. *Biol. Psychiatry* **82**, 885–894 (2017).